Editas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting
Editas Medicine, Inc. (EDIT)
Last editas medicine, inc. earnings: 2/26 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.editasmedicine.com
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the Company will present preclinical data on its progress in the development of cell therapy medicines for the treatment of cancer at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting being held in Washington, D.C., and virtually, November 10-14, 2021. The Company will present a poster on its new method to drive high-level constitutive CD16 expression on the surface of iPSC-derived natural killer (iNK) cells through transgene knock-in (KI) at the GAPDH locus using an Editas-engineered AsCas12a. New preclinical data demonstrated that CD16 KI confers significantly increased cytotoxic activity in iNK cells against tumor cells compared with wild type iNK cells. Full details of the Editas Medicine presentation can be accessed on the SITC website at https://sitc.sitcancer.org/2021/abstracts/titles/. Poster Presentation:Title:
Show less
Read more
Impact Snapshot
Event Time:
EDIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDIT alerts
High impacting Editas Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
EDIT
News
- Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer [Yahoo! Finance]Yahoo! Finance
- Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update [Yahoo! Finance]Yahoo! Finance
- 1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right. [Yahoo! Finance]Yahoo! Finance
- Insider Sells Shares of Editas Medicine Inc (EDIT) [Yahoo! Finance]Yahoo! Finance
EDIT
Earnings
- 2/28/24 - Beat
EDIT
Sec Filings
- 4/10/24 - Form SC
- 3/5/24 - Form 4
- 3/5/24 - Form 4
- EDIT's page on the SEC website